ArticleJournal of cancer research and clinical oncology2015
Detection of relapse after hematopoietic stem cell transplantation in childhood by monitoring of WT1 expression and chimerism.
Article in Journal of cancer research and clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 7 citations in OpenAlex.
- Peripheral blood marker of residual acute leukemia after hematopoietic cell transplantation using multi-plex digital droplet PCR.Frontiers in immunology · 2022Article
- Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML.Bone marrow transplantation · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe measurement of minimal residual disease after hematopoietic stem cell transplantation is crucial for the prevention of hematological relapses. But many methods are limited to certain groups of patients. We present a comparison of two markers which are universally applicable: WT1 expression and chimerism status.
methodsWe analyzed 1,848 peripheral blood and bone marrow samples of 148 children, adolescents and young adults with malignant hematological diseases. Median follow-up time was 739 days after transplantation.
resultsAll patients suffering from hematological relapse showed high WT1 levels. Approximately half (51%) of the 37 relapses could have been detected early through an increase in WT1 expression. WT1 kinetics revealed to be more specific than single elevated WT1 levels (p < 0.05) and chimerism analysis (p < 0.05). Combined with chimerism analysis, 74% of relapses were detectable in advance. Elevated WT1 expression levels after transplantation reached the highest sensitivity (64.9%) as a single marker, although differences were not significant. When the dynamics of both markers as well as any elevated WT1 expression were taken into account, a sensitivity of 81.5% and a specificity of 83.7% were obtained.
conclusionsHence, we conclude that WT1 is a useful marker for monitoring of minimal residual disease after transplantation, if specific targets are not available. WT1 expression and chimerism status should be mutually evaluated to decide about immunotherapeutic interventions aimed at preventing morphological relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.